Pricing Log in Create free account

Aurinia Pharmaceuticals Inc (AUPH) vs Immunome, Inc. (IMNM)

Aurinia Pharmaceuticals Inc and Immunome, Inc. are both Biotechnology companies. Aurinia Pharmaceuticals Inc and Immunome, Inc. are of similar size ($2.2B and $2.1B). Immunome, Inc. has negative trailing earnings, so its P/E is not meaningful; Aurinia Pharmaceuticals Inc trades at 6.8×. Aurinia Pharmaceuticals Inc grew revenue faster over the last twelve months: 21.0% against 16.7%. Aurinia Pharmaceuticals Inc has the higher net margin (97.7% vs 0.00%) and the higher return on invested capital (43.0% vs −3,323.0%). Across the 17 metrics below, Aurinia Pharmaceuticals Inc leads on 14 and Immunome, Inc. on 3.

Valuation

Metric AUPH IMNM Biotechnology median
P/E 6.78 n/m 10.26
P/S 6.72 162.50 9.18
P/B 3.29 3.90 2.05
Price to free cash flow 12.22 n/m 24.81
EV/EBITDA 10.49 n/m 0.65
EV/Sales 5.33 121.23 8.98
Earnings yield 14.74% (14.01%) (34.89%)
Free cash flow yield 8.18% (10.71%) (24.52%)

Profitability

Metric AUPH IMNM Biotechnology median
Gross margin 90.62% 100.00% 65.16%
Operating margin 44.78% 0.00% 0.00%
Net margin 97.68% 0.00% 0.00%
Free cash flow margin 55.02% 0.00% 0.00%
Return on equity 61.42% (64.03%) (50.12%)
Return on assets 46.45% (59.03%) (45.60%)
Return on invested capital 42.95% (3,322.99%) 0.00%

Growth

Metric AUPH IMNM Biotechnology median
Revenue growth (TTM) 21.04% 16.74% 6.26%
EPS growth (last fiscal year) 5,075.00% 51.40% 29.88%
Revenue growth, 5-year CAGR 41.38% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AUPH IMNM Biotechnology median
Debt to equity 0.06 0.00 0.00
Current ratio 6.12 15.08 4.89
Net debt to EBITDA (2.58) 2.92 1.01

Dividend

Metric AUPH IMNM Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AUPH IMNM Biotechnology median
Market cap 2.17b 2.11b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack